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Abstract
Instrumental variable is an essential tool for addressing unmeasured confounding in obser-
vational studies. Two stage predictor substitution (2SPS) estimator and two stage residual
inclusion(2SRI) are two commonly used approaches in applying instrumental variables. Re-
cently 2SPS was studied under the additive hazards model in the presence of competing risks
of time-to-events data, where linearity was assumed for the relationship between the treatment
and the instrument variable. This assumption may not be the most appropriate when we have
binary treatments. In this paper, we consider the 2SRI estimator under the additive hazards
model for general survival data and in the presence of competing risks, which allows generalized
linear models for the relation between the treatment and the instrumental variable. We derive
the asymptotic properties including a closed-form asymptotic variance estimate for the 2SRI
estimator. We carry out numerical studies in finite samples, and apply our methodology to
the linked Surveillance, Epidemiology and End Results (SEER) - Medicare database comparing
radical prostatectomy versus conservative treatment in early-stage prostate cancer patients.
Keywords: Additive hazards model; Asymptotic variance; Causal inference; Endogeneity; Un-
observed confounding.
1 Introduction
Interpreting the causal meaning of a treatment or exposure is straightforward under the randomized
trials, because the randomization guarantees that there are no confounders for the exposure or
treatment of interest. However, randomized experiment is not always feasible in practice. In
observational studies issues such as endogeneity or potential confounding will arise. Instrumental
variable (IV) is a useful method in some of these settings1, including when we may have unmeasured
confounders. It finds increasing application in research on health care practices (see for example
Hogan and Lancaster 2 , Stukel et al. 3) including comparative effectiveness studies, and also in
genetic studies where certain genes are used as IV for Mendelian randomization4–6.
Figure 1 illustrates a typical setting where IV methods can be applied. It is called a causal
directed acyclic graph, where the nodes represent random variables, arrows represent direct causal
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effect, in such a way so that the common cause of any two nodes is included in the graph. In Figure
1 Xe is the exposure we are interested in testing the causal effect on the survival time outcome T ,
and we use a dashed line to represent the uncertainty of causation. In addition, Xo is the observed
confounder, Xu the unobserved confounder. XI is the instrument variable which has to satisfy the
following three conditions: 1) XI is associated with Xe, 2) XI doesn’t affect T except through its
potential effect on Xe, and 3) XI and Xu do not share causes.
There are two commonly used IV approaches: two-stage predictor substitution (2SPS), and two-
stage residual inclusion (2SRI). For survival outcomes Tchetgen Tchetgen et al. 7 considered these
two methods under the additive hazards model, and gave conditions under which the causal param-
eters of interest can be correctly estimated. We note that while the Cox proportional hazards model
has been more widely used in practice for survival data, an important appeal of additive hazards
models is that unlike proportional hazards, a hazards difference is a collapsible effect measure.7,8
This means that when there is an unobserved (exogenous) covariate for the survival outcome, inte-
grating out this covariate under the additive hazards model still gives a model satisfying the additive
hazards assumption. But this has long been known not to be the case for the proportional hazards
model.9–15 In 2SPS under the additive hazards model the exposure is substituted by its predic-
tion given the IV, and included in the model as a covariate, together with possibly other observed
confounders. Li et al. 16 investigated its large sample properties under the additive hazards model.
Zheng et al. 17 considered 2SPS under competing risks.
The 2SRI is different from 2SPS in that instead of the predicted exposure, the residual from
regressing the exposure on the IV(i.e. first stage) is included as an extra term in the additive
hazards model, in addition to the exposure and possibly other observed confounders. This was
considered more suitable for binary or discrete exposures7,18, when generalized linear models (GLM)
for example are used in the first stage. Note that linear regression is used in the first stage of 2SPS,
and therefore it is more suitable for continuous exposures. Very recently Jiang et al. 19 studied the
2SRI estimator with linear regression in the first stage for survival data. Our goal in this paper is
to study the 2SRI estimator with GLM in the first stage, and also to develop the methodology for
competing risks data.
This work was motivated by the desire to conduct comparative effectiveness research in large
observational databases. In the field of oncology we lack gold standard randomized clinical trials in
many clinical scenarios to optimally inform clinical decision making. With the lack of randomized
trials investigators turn to comparative effectiveness with large observational data sets such as the
linked (Surveillance, Epidemiology, and End Results) SEER-Medicare database. These databases
include information on the specifics of cancer, staging, treatment, patient comorbidity, as well as
information on long-term outcomes including toxicity and survival. Despite this wealth of informa-
tion, these databases do not contain information on unmeasured confounding factors such as patient
weight, smoking status, diet, exercise, patient compliance with treatment, and patient performance
status. These unmeasured confounders can substantially influence outcomes (in particular survival),
adding bias to comparative effectiveness research using observational data. Recently Hadley et al. 20
compared aggressive (radical prostatectomy) versus conservative treatments of prostate cancer with
SEER-Medicare linked data. The question of radical prostatectomy versus conservative treatment
has been addressed in randomized clinical trials which demonstrate no clear survival advantage
for either treatment approach.21,22Hadley found IV to be a useful technique as compared to for
example propensity scores in adjustment for confounding in such data. Proportional hazards model
was used in their analysis which, as pointed out by Li et al. 16 as well as explained above, due to
the noncollapsibility is not suitable for the two-stage approaches. We would like to instead consider
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the additive hazards model for the reasons given earlier. Since the treatment choices are binary,
we would like to use the 2SRI estimator, both for overall survival, and for cancer specific mortality.
For these purposes we need to develop the inference procedure under the model for both general
survival data and under competing risks.
The rest of the paper is organized as follows. In section 2 we describe the assumptions needed
for the 2SRI approach under the additive hazards model for general survival data with right censor-
ing, and we study the asymptotic behavior including consistency and asymptotic normality of the
2SRI estimator. Following that, we extend the results to competing risks data in Section 3 under
subdistribution hazard modeling. For both settings we provide a closed-form variance estimate of
the 2SRI estimator. Section 4 contains finite sample simulation results, and Section 5 the analysis
of the SEER-Medicare data. Section 6 contains some further discussion. All technical details are
provided in the Appendix.
2 Additive hazards model for survival data
In the presence of possible right censoring, let T and C be the failure time and the censoring time
random variables, respectively. We can only observe T ∗ = min(T,C) and δ = 1{T≤C}. Similar
to the setting in Figure 1, denote Xe as the exposure variable, whose causal effect is of primary
interest, XI as the IV, and Xo as the (vector of) observed confounders. Our observed data for each
individual is {T ∗i , δi, Xei, Xoi, XIi} (i = 1, ..., n), which we assume are independent and identically
distributed. In this section, we will assume that T and C are independent conditional on Xe, XI
and Xo. Under the additive hazards model
23–25, the hazard function of T given Xe, XI , Xo and the
unobserved confounders is assumed to be in the form
λ(t|Xe, XI , Xo, Xu) = λ0(t) + βeXe + β>o Xo +Xu, (1)
where Xu is a function of the unobserved confounders. We assume that Xu is independent of Xo
and XI . Denote
∆ = Xe − E(Xe|XI , Xo). (2)
Following Tchetgen Tchetgen et al. 7 we put a key assumption on Xu:
Xu = ρ0∆ + . (3)
where  is an error term independent of Xe, XI and Xo. Proposition 2 in the Appendix shows that
integrating out Xu we have
λ(t|Xe, XI , Xo) = λ¯0(t) + βeXe + βo>Xo + ρ0∆. (4)
Note that the same coefficient βe (and βo) from (1) is remained in (4).
The error term ∆ in (4) is not readily available from the data. Nonetheless we can ‘estimate’
∆ and use this estimate as a substitute. For this we need to impose an assumption on the form of
E(Xe|XI , Xo), for example,
g(E(Xe|XI , Xo)) = αc + αIXI + α>o Xo, (5)
where g(·) is a link function.
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The two stage residual inclusion (2SRI) estimator is then defined as follows: in the first stage,
we fit model (5) and obtain
∆ˆ = Xe − Xˆe = Xe − Eˆ(Xe|XI , Xo). (6)
Then in the second stage, we fit (4) with ∆ replaced by ∆ˆ.
Denote Zi = [Xei,X
>
oi, ∆ˆi]
> the regressors in (4) with ∆ replaced by ∆ˆ, X˜i = [1, XIi, X>oi ]
> the
regressors in (5). Let Ni(t) = 1{T ∗i ≤t,δi=1} be the counting process, and Yi(t) = 1{T ∗i ≥t} the at-risk
process. Define the filtration Ft = σ{Ni(u), Yi(u), XIi, Xoi, Xei, u ≤ t, i = 1, .., n}. By the usual
counting process theory, Mi(t) = Ni(t)−
∫ t
0 Yi(u)λi(u)du is a mean zero martingale with respect to
the filtration Ft. Under the additive hazards model the estimating equation for β = (βe,β>o , ρ0)>
in (4) is
U(β) =
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))(dNi(t)− Yi(t)β>Zidt), (7)
where Z¯(t) =
n∑
l=1
ZlYl(t)/
n∑
l=1
Yl(t). This gives our estimator
βˆ =
{ n∑
i=1
∫ 1
0
Yi(t)(Zi − Z¯(t))⊗2dt
}−1{ n∑
i=1
∫ 1
0
(Zi − Z¯(t))dNi(t)
}
. (8)
In the following we show that βˆ is consistent for the true β and therefore βˆe is consistent for the
causal parameter βe. The estimator is also asymptotically normal and we provide a closed form
expression for its asymptotic variance.
In addition to β, the cumulative baseline hazard function Λ0(t) =
∫ t
0 λ¯0(s)ds can be estimated
by
Λˆ0(t) =
n∑
i=1
∫ t
0
1∑n
j=1 Yj(u)
dNi(u)− βˆ>
∫ t
0
Z¯(u)du. (9)
Using this we can also estimate the conditional survival function given the observed variables x =
(xe,x
>
o , xI)
>, the value of the variables of a future patient whose survival we are interested in
predicting:
Sˆ(t|x) = exp(−Λˆ0(t)− βˆ>zt), (10)
where z = (xe,x
>
o , xe − Eˆ(Xe|xI ,xo))>. Note that under the additive hazards model Λˆ0(t) can be
negative, or the estimated survival function Sˆ(t|x) not decreasing. Therefore we follow the approach
of Lin and Ying 25 and use a modified Λˆ∗0(t) = max0≤s≤t Λˆ0(s), and Sˆ∗(t|x) = min0≤s≤t Sˆ(s|x).
Under regularity condition, the modified version is asymptotically equivalent to the original version.
Now we state our main results below.
Theorem 1. Under (1), (3), (5) and regularity conditions 1, 4 and 5 given in the Appendix, the
two stage residual inclusion estimator βˆ is consistent for the true value of β in (4), denoted by βT ,
i.e. βˆ → βT in probability as n→∞.
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Theorem 2. Under (1), (3), (5) and Conditions 1,4,5,
√
n(βˆ − βT ) is asymptotically normally
distributed with asymptotic covariance matrix that can be consistently estimated by Ωˆ−1(Σˆ1+Σˆ2)Ωˆ−1,
where
Ωˆ =
1
n
n∑
i=1
∫ 1
0
Yi(t)(Zi − Z¯(t))⊗2dt, (11)
Σˆ1 =
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))⊗2dNi(t), (12)
Σˆ2 = ΨˆΘˆΨˆ
>, (13)
Ψˆ =
ρˆ0
n
n∑
i=1
{∫ 1
0
Yi(t)(Zi − Z¯(t))dt
}
X˜>i (g
−1)′(X˜>i αˆ), (14)
α = (αc, αI , α
>
o )
>, Θˆ is the estimated covariance matrix of
√
n(αˆ − αT ) from the first stage, and
(g−1)′ is the derivative of the inverse function of g.
Remark 1. Note that Θˆ can typically be obtained when using software for fitting linear or generalized
linear regression models in the first stage. For linear regression of Xe on XI and Xo in (5), g(y) = y,
so (g−1)′ ≡ 1. For logistic regression (g−1)′(y) = exp(y)/{1 + exp(y)}2.
Theorem 3. For a new observation x, Under (1), (3), (5) and Conditions 1,4,5, the estimated
survival function in (10) converges to S(t|x) uniformly and the process √n{Sˆ(·|x)−S(·|x)} converges
weakly to a zero-mean Gaussian process whose covariance function at (t, s), where 0 ≤ s ≤ t, can
be consistently estimated by
Sˆ(t|x)Sˆ(s|x)
{
n
n∑
i=1
∫ s
0
1
(
∑n
j=1 Yj(u))
2
dNi(u) + Gˆ
>(t)Ωˆ−1(Σˆ1 + Σˆ2)Ωˆ−1Gˆ(s)
+Eˆ>(t)ΘˆEˆ(s) + Gˆ>(t)Ωˆ−1Dˆ(s) + Gˆ>(s)Ωˆ−1Dˆ(t)
}
, (15)
where
Dˆ(t) =
n∑
i=1
∫ t
0
Zi − Z¯(u)∑n
j=1 Yj(u)
dNi(u), (16)
Eˆ(t) = ρˆ0
n∑
i=1
X˜i(g
−1)′(X˜>i αˆ)
∫ t
0
Yi(u)∑n
j=1 Yj(u)
du, (17)
Gˆ(t) =
∫ t
0
(z − Z¯(u))du. (18)
Remark 2. In forming the confidence interval (CI) for S(t|x), we can take the log-log transformation
of Sˆ(t|x) and use Delta method to obtain the confidence interval of log Λ(t|x). This way the
transformed-back confidence interval of Sˆ(t|x) is guaranteed to be within the range of [0, 1].
The asymptotic results for the cumulative baseline hazard estimator is in the appendix.
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3 Competing risks
We now consider competing risks data. As before let T and C be the failure time and the censoring
time, respectively. In addition let J ∈ {1, ...,K} to be the indicator for cause of failure, and J = 1
will be our cause of interest. Denote X = (Xe, XI , Xo, Xu), F1(t|X) = P (T ≤ t, J = 1|X), and
let λ1(t|X) = −d log{1 − F1(t|X)}/dt be the subdistribution hazard. In principle we may assume
that C and T are independent conditional on all the observed covariates, but for the estimation
approach below we will make use of the marginal Kaplan-Meier estimate of the distribution of C.
Therefore we will make the stronger assumption that C and T are independent; we will discuss the
relaxation of this assumption later.
Similar to Section 2 we assume that
λ1(t|Xe, XI , Xo, Xu) = λ10(t) + βeXe + βoXo +Xu. (19)
This is the additive subdistribution hazards model. Keeping the same notation as in (2) and
assumption (3), we have according to Proposition 4,
λ1(t|Xe, XI , Xo) = λ¯10(t) + βeXe + β¯o>Xo + ρ0∆. (20)
Note that although the derivation of Proposition 4 is similar to that of Proposition 2, this is a
new result to our best knowledge and the 2SRI approach has not been previously considered under
competing risks in the literature.
In the 2SRI approach for competing risks data here, the first stage is the same as that in Section
2, and we replace ∆ by ∆ˆ to fit (20). Our observed data are {T ∗i , δi, δiJi, Xei, Xoi, XIi}1≤i≤n. The
following are common quantities used in the regression modeling and inference of the subdistribution
hazard function. With a slight abuse of notation in this section, define the event time process as
Ni(t) = 1{Ti≤t,Ji=1}, and the at-risk process as Yi(t) = 1 − Ni(t−) (note that these have different
meanings from Section 2). Let ri(t) = 1{Ci≥Ti∧t} denote an individual not censored or yet, so
that both ri(t)Ni(t) and ri(t)Yi(t) are computable from the observed data at any time t. Define
wi(t) = ri(t)G(t)/G(T
∗
i ∧ t), and wˆi(t) = ri(t)Gˆ(t)/Gˆ(T ∗i ∧ t), where G(t) = P(C ≥ t) and Gˆ(t) is
the Kaplan-Meier estimate for G(t) using {T ∗i , 1− δi}1≤i≤n.
We will use M1i (t) to denote the martingale for the i-th object with respect to the complete-
data filtration, that is, F1(t) = σ{Ni(u), Yi(u), Xei, XIi, Xoi, u ≤ t,∀ 1 ≤ i ≤ n}. We will also
use M ci (t) to denote the martingale for the censoring related process of the i-th subject, M
c
i (t) =
N ci (t) −
∫ t
0 1{T ∗i ≥u}dΛ
c(u), where N ci (t) = 1{T ∗i ≤t,δi=0} is the censoring counting process, Λ
c(t) is
the cumulative hazard function of the censoring distribution. The censoring filtration is Fc(t) =
σ{1{T ∗i ≥u},1{T ∗i ≤u,δi=0}, Xei, XIi, Xoi, u ≤ t,∀ 1 ≤ i ≤ n}.
The estimating function for β = (βe, β
>
o , ρ0)
> can be written as17,26
U(β) =
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))wˆi(t)(dNi(t)− Yi(t)β>Zidt), (21)
where Zi is the same as defined in Section 2, Z¯(t) =
∑n
l=1 Zlwˆl(t)Yl(t)∑n
l=1 wˆl(t)Yl(t)
. Therefore,
βˆ =
{ n∑
i=1
∫ 1
0
wˆi(t)Yi(t)(Zi − Z¯(t))⊗2dt
}−1{ n∑
i=1
∫ 1
0
(Zi − Z¯(t))wˆi(t)dNi(t)
}
. (22)
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The baseline cumulative hazard function Λ10 =
∫ ·
0 λ10 is then estimated by
Λˆ10(t) =
n∑
i=1
∫ t
0
wˆi(u)∑n
j=1 wˆj(u)Yj(u)
dNi(u)− βˆ>
∫ t
0
Z¯(u)du. (23)
Therefore the estimated cumulative incidence function (CIF) is
Fˆ1(t|x) = 1− Sˆ1(t|x) = 1− exp(−Λˆ10(t)− βˆ>zt), (24)
where z = (xe,x
>
o , xe − Eˆ(xe|xI ,xo))>, and (xe,xo, xI) is the value of the variables of a future
patient whose CIF we are interested in predicting. We use the same modified version Λˆ∗10(t) =
max0≤s≤t Λˆ10(s) and Fˆ ∗1 (t|x) = max0≤s≤t Fˆ1(s|x) as in Section 2 to ensure that the estimated
hazard is non-negative. Now we state our main results below.
Theorem 4. Under (19), (3), (5) and Conditions 1,6,7, the two stage residual inclusion estimator
βˆ is consistent for the true value of β in (4), denoted by βT , i.e. βˆ → βT in probability as n→∞.
Theorem 5. Under (19), (3), (5) and Conditions 1,6,7,
√
n(βˆ − βT ) is asymptotically normally
distributed with asymptotic covariance matrix that can be consistently estimated by Ωˆ−1(Σˆ1 + Σˆ2 +
Σˆ3)Ωˆ
−1, where
Ωˆ =
1
n
n∑
i=1
∫ 1
0
wˆi(t)Yi(t)(Zi − Z¯(t))⊗2dt, (25)
Σˆ1 =
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))⊗2wˆi(t)dNi(t), (26)
Σˆ2 = ΨˆΘˆΨˆ
>, (27)
Σˆ3 =
1
n
n∑
i=1
∫ 1
0
( qˆ(t)
pˆi(t)
)⊗2
dN ci (t), (28)
Ψˆ =
ρˆ0
n
n∑
i=1
{∫ 1
0
wˆi(t)Yi(t)(Zi − Z¯(t))dt
}
X˜>i (g
−1)′(X˜>i αˆ), (29)
qˆ(t) = − 1
n
n∑
i=1
∫ 1
0
1{T ∗i <t≤u}wˆi(u)
(
Zi − Z¯(u)
)
dMˆi(u), (30)
pˆi(t) =
1
n
n∑
i=1
1{T ∗i ≥t}, (31)
Mˆi(t) = Ni(t)−
∫ t
0
Yi(u)(dΛˆ10(u) + βˆ
>Zidu), (32)
and Θˆ is the estimated variance-covariance matrix of
√
n(αˆ− αT ) from the first stage.
Theorem 6. For a new observation x, under (19), (3), (5) and Conditions 1,6,7, the estimated CIF
in (24) converges to F1(t|x) uniformly and the process
√
n{Fˆ1(·|x)−F1(·|x)} converges weakly to a
zero-mean Gaussian process whose covariance function at (t, s), where 0 ≤ s ≤ t, can be consistently
7
estimated by
(1− Fˆ1(t|x))(1− Fˆ1(s|x))
{∫ s
0
n
∑n
i=1 wˆ
2
i (u)dNi(u)
(
∑n
j=1 wˆj(u)Yj(u))
2
+ Gˆ>(t)Ωˆ−1(Σˆ1 + Σˆ2 + Σˆ3)Ωˆ−1Gˆ(s)
+n
n∑
i=1
∫ 1
0
qˆt(u)qˆs(u)
pˆi2(u)
dN ci (u) + Eˆ
>(t)ΘˆEˆ(s) + Gˆ>(t)Ωˆ−1Dˆ(s) + Gˆ>(s)Ωˆ−1Dˆ(t)
}
, (33)
where
Dˆ(t) =
n∑
i=1
∫ t
0
(Zi − Z¯(u))wˆi(u)∑n
j=1 wˆj(u)Yj(u)
dNi(u), (34)
Eˆ(t) = ρˆ0
n∑
i=1
X˜i(g
−1)′(X˜>i αˆ)
∫ t
0
wˆi(u)Yi(u)∑n
j=1 wˆj(u)Yj(u)
du, (35)
Gˆ(t) =
∫ t
0
(z − Z¯(u))du, (36)
qˆt(u) =
1
n
n∑
i=1
∫ t
0
1{T ∗i <u≤v}wˆi(v)∑n
j=1 wˆj(v)Yj(v)
dMˆi(v). (37)
Remark 3. As in Section 2 we can take the log-log transformation of 1 − Fˆ1(t|x), and use Delta
method to obtain the confidence interval of log Λ1(t|x). This way the transformed-back confidence
interval of 1− Fˆ1(t|x) is guaranteed to be within the range of [0, 1].
The asymptotic results for the cumulative baseline hazard estimator is in the appendix.
4 Simulation
We are in the process of completing an R package for our estimators. The following numerical
results were obtained using the program which is the core of the package.
To study the performance of our estimators under both survival and competing risks settings,
we carried out simulation studies with sample size 100, 200, 400, 800, 1200, and repeated 1000 times
for each sample size. We provided in the tables the bias of the estimator, the empirical variance of
the estimator from the 1000 repeats, the mean of the variance estimate, and the coverage rate of
the nominal 95% confidence intervals.
4.1 Regular survival model
For this part without competing risks, we considered the following three scenarios.
Scenario I: We sampled XI , Xo from independent standard normal distributions, set α =
[1, 1, 0.5]>, and generated Xe = [1, XI , Xo]α> + ∆, where ∆ ∼ N(0, 0.2) was independent of
XI , Xo. We simulated Xu according to (3) with independent i ∼ N(0, 0.1), and ρ0 = 1. We
set β = [1, 0.5, 1.5]> and the baseline hazard λ0(t) ≡ 10.5 in (1) to generate the survival time T .
There was no censoring in this case.
Scenario II: Similar to I above, but with α = [0.25, 0.3, 0.2]>, β = [0.5, 0.2, 0.3]>, and λ0(t) ≡
5t+ 5. The censoring distribution followed exponential with rate of 2 so that the censoring rate is
around 40%.
8
Scenario III: We generated binary exposure as follows. First we sampled XI from Bernoulli
distribution with P (XI = 1) = 0.5, and independent Xo from standard normal distribution. We
generated Xe from
Xei|XIi, Xoi ∼ Bern
( 1
1 + exp(−(α0 + αiXIi + αoXoi))
)
.
with α = [1, 0.5, 1]>. We then simulated
Xui = ρ0{Xei − E(Xei|XIi, Xoi)}+ i,
with ρ0 = 1 and independent i ∼ N(0, 0.1). Finally we generate the survival time by setting
β = [1, 0.5, 1.5]> and the baseline hazard λ0(t) ≡ 10.5. The censoring distribution was exponential
with rate of 5 so that the censoring rate is around 30%.
4.2 Competing risks model
For the competing risks model, let
P(J = 1|X) = 1− exp(−
∫ t0
0
λ10(u)du− (βe1Xe + βo1Xo + βu1Xu)t0), (38)
and P(J = 2|X) = 1− P(J = 1|X). Here t0 is a maximum follow-up time. We then simulated the
event time data from the following subdistributions:
F (t|J = 1,X) = 1− exp(−
∫ min(t,t0)
0 λ10(u)du− (βe1Xe + βo1Xo + βu1Xu) min(t, t0))
1− exp(− ∫ t00 λ10(u)du− (βe1Xe + βo1Xo + βu1Xu)t0) , (39)
F (t|J = 2,X) = 1− exp(−(λ20 + βe2Xe + βo2Xo + βu2Xu) min(t, t0))
1− exp(−(λ20 + βe2Xe + βo2Xo + βu2Xu)t0) . (40)
Note that
F (t, J = 1|X) = 1− exp(−
∫ min(t,t0)
0
λ10(u)du− (βe1Xe + βo1Xo + βu1Xu) min(t, t0)). (41)
Note that the maximum follow-up time t0 is necessary because under the additive hazards model
Λ1(t|Z) = Λ10(t) + β>Zt goes to infinity as t→∞, implying that limt→∞ F1(t|Z) = 1, which is no
longer a subdistribution function.
Scenario I: Similar to Scenario I under the regular survival model but with α = [1.5, 1, 0.7]>,
β1 = [1, 0.5, 0.75]
> and λ10(t) ≡ 11 for cause 1, and β2 = [1.2, 1, 1.3]> and λ20 = 15 for cause 2. We
set t0 = 0.095. There was no censoring, and the cause 1 event rate was around 60%.
Scenario II: similar to I above, but with α = [1, 1, 0.5]>, β1 = [1, 0.5, 0.75]> and λ10(t) = 5t+ 10
for cause 1, and the same as in Scenario I for cause 2. We set t0 = 0.06. The censoring distribution
was exponential with rate of 1. The cause 1 event rate was around 28% and censoring rate around
38%.
Scenario III: Similar to Scenario III under the regular survival model, but with α = [−1, 2, 1]>,
β1 = [1, 0.5, 0.75]
> and λ10(t) ≡ 10 for cause 1, and the same as in Scenario I, II for cause 2. We
set t0 = 0.06. The censoring distribution was exponential with rate of 25. The cause 1 event rate
was around 26% and censoring rate aroung 44%.
9
4.3 Simulation results
The results are summarized in Table 1 and 2, respectively. From the tables we can see that as
the sample size increases the bias goes down, and the variance estimate also becomes closer to the
empirical variance. The coverage rate is quite close to nominal 95% level in all cases. The variance
of the estimator becomes larger in Scenario III both with or without competing risks, probably
because we have a binary treatment, which leads to a error term with large variance, compared to
the error terms in other scenarios. Nonetheless the variance estimate still works well. In general
our estimator behaves well under all the finite-sample settings considered.
5 SEER-Medicare data analysis
For this analysis we consider prostate cancer patients with localized non-metastatic disease identified
from the linked SEER-Medicare database diagnosed between 2000-2011 and followed up through
12/31/2013. The variables included were age, race/ethnicity, marital status, tumor stage, tumor
grade, Prior Charlson comorbidity score measured during the year prior to diagnosis, year of di-
agnosis, and hospital referral regions. The hospital referral region was an important variable for
us to construct the instrumental variable. Hospital referral regions represents a set of contiguous
zip codes around a major hospital. Following Hadley et al. 20 we restricted the analysis to early
stage (T1 and T2) patients, aged 66 to 74 years, as well as eliminated patients in geographic areas
with fewer than 50 patients over the entire observation period. This led to an overall sample size
of n = 29806. Among them 493 (1.65%) patients died due to cancer, 2066 (6.93%) died due to
other causes, and the remaining 27247 (91.4%) were alive at the end of the follow-up. There were
four types of treatments: surgery, radiation, chemotherapy and hormonal therapy; 10977 people
received surgery, 21357 radiation, 9577 chemotherapy, and 9527 hormonal therapy. Note that some
patients received more than one treatment. Following Hadley et al. 20 we will label patients who
received surgery as “radical prostatectomy” and the remaining “conservative management”. We
will then compare the effects of these two treatments on the time to death for all causes and due
to cancer, respectively. A summary of the patient characteristics is presented in Table 3. It can be
seen that patients who received surgery tended to be younger, married, non-black, have T2 stage,
well differentiated tumor grade, comorbidity score 0, and diagnosed no later than 2005. Hadley
et al. 20 showed that the treatment pattern varied by hospital referral regions, beyond what was
captured by the patient characteristics in Table 3.
For comparison purposes we first fitted the additive hazards model including the variables in
Table 3 and all their pairwise interactions, but without using any IV. It turned out that the treat-
ment had a significant effect with p-value of 0.001 for all causes of death. On the other hand the
treatment effect was not significantly different from zero for our data with p-value of 0.13 for cancer
specific survival. We note that in Hadley et al. 20 the treatment had a significant effect on both
overall survival and cancer specific survival; our data was a later export than those used by Hadley
et al. 20 (diagnosed between 1995 and 2003) from the linked database. In addition, Hadley et al. 20
used the Cox multiplicative hazards model as opposed to our additive hazards model.
We now consider the 2SRI approach. We used the same instrumental variable as in Hadley
et al. 20 . Specifically, we constructed the IV as follows. We first applied logistic regression to obtain
the predicted probability for conservative management given covariates including age, race/ethnicity,
marital status, tumor stage, tumor grade description, Prior Charlson comorbidity score, year of
diagnosis and all the two-way interactions. Then for each hospital referral region and each year, we
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calculated the difference between the proportion of patients receiving conservative management and
the average predicted probability of conservative management. Clearly, a larger difference indicated
that the corresponding hospital referral region favored the conservative management more than
those with a smaller difference. Therefore this difference was likely correlated with the treatment
a patient received and, on the other hand, this difference was unlikely to directly influence the
survival of an individual patient beyond the treatment assignment. For use as an IV we lagged this
difference for one year for the patients coming from the same hospital referral region. Therefore,
the data that we used to analysis survival were patients diagnosed from 2001 to 2011.
We then performed the first step of the IV analysis, using logistic regression of treatment on the
IV obtained above, together with the other observed confounders including age, race or ethnicity,
marital status, tumor stage, grade description and Prior Charlson comorbidity score, year of diag-
nosis and all two-way interactions. We found that the instrument had an extremely significant effect
on the treatment with p-values less than 2×10−16, indicating likely a strong IV. We then subtracted
the predicted probability of treatment from the observed treatment to obtained the residuals. In
the second step, we included this residual term together with the treatment and all the confounders
and their pairwise interactions to fit the survival models. The results for overall survival are shown
in Table 4, and for cancer specific survival in Table 5.
From the tables we see that the causal effect of treatment remained?? significant for overall
survival, although the p-value increased from 0.001 to 0.042. The p-value for the causal effect of
treatment on cancer specific survival also increased from 0.13 to 0.41. The differences between the
IV analysis results and the initial analysis results earlier indicate that there were likely unobserved
confounders for the treatment effect on both overall and cancer specific survival, beyond those
captured in Table 3 (and their interactions).
Finally, Figure 2 illustrates the predicted overall survival as well as cancer specific cumulative
incidence function for a patient who received radical prostatectomy, was diagnosed in 2001, aged
71, white, with ‘other’ marital status, tumor stage T2, moderately differentiated tumor, Charlson
comorbidity score 2, and instrument value 0.0.3429. In reality the patient survived for 95 months,
and died of other causes.
6 Discussion
In this paper we have developed statistical inference procedures for the 2SRI IV estimator under
GLM in the first stage and additive hazards model in the second stage for survival data that was
conceptually described in Tchetgen Tchetgen et al. 7 . We have also extended the approach to
competing risks data under the additive subdistribution hazards model. An R package is being
completed that computes these estimators and their closed-form estimated asymptotic variances, as
well as prediction under these models given the observed covariates. Our simulation results show the
satisfactory performance of the procedures, and the SEER-Medicare analysis shows the usefulness
of the approaches.
The causal effect of interest βe that we have considered in this work is conditional on the
unobserved confounder Xu, although from (4) and (20) we may also understand it as conditional
on the observed variables. This seems reasonable in our comparative effectiveness settings, where
a relatively large number of observed confounders are typically considered. Cai et al. 27 considered
the setting for compliance in randomized clinical trials with binary outcomes, and pointed out that
the 2SPS and 2SRI approaches may not estimate the causal odds ratio among compliers under the
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principal stratification framework.1,28 Future work may consider similar analysis under the additive
hazards model.
Under competing risks and using subdistribution hazards modeling, weights based on the esti-
mated censoring distribution are needed in order to consistently estimate the regression coefficients.
The marginal Kaplan-Meier estimate we used requires independent censoring. Alternatively one
may estimate the conditional distribution of censoring given covariates using, for example, semi-
parametric survival models. Recently Nguyen and Gillen 29 proposed to estimate this conditional
distribution nonparametrically using a survival tree approach. When any of these estimates are
used, the assumption on censoring distribution can then be relaxed to be conditionally independent
of failure time (and type/cause) given the covariates.
All our technical proofs are compatible with time-dependent covariates. However, the causal
inference problem is more complex with time-varying confounders and time-varying treatments,
especially if the later confounders are affected by the earlier treatments.30 To our best knowledge
time-varying instrument variable method has not been developed in the literature.
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7 Appendix
7.1 Preparations
The following results are either from or easy consequences of Fleming and Harrington 31 . The
predictable variation process 〈 〉 and quadratic variation process [ ] are also defined in Fleming and
Harrington 31 .
Lemma 1. Assume that for each t ≥ 0, given Ft−, {dN1(t), ..., dNn(t)} are independent 0, 1 random
variables, set Mj = Nj −Aj, where Aj is the compensator for Nj. Then for any i 6= j and t ≥ 0,
〈Mi,Mj〉(t) = 0, a.s. (42)
Lemma 2. Let M(t) be a martingale with respect to the filtration F(t), H(t) be a predictable process,
then the predictable variation process of the martingale integral
∫ t
0 H(s)dM(s) is
〈
∫ t
0
H(s)dM(s)〉 =
∫ t
0
H2(s)d〈M〉(s). (43)
Lemma 3. Let M1(t), M2(t) be martingales with respect to the filtration F(t), H1(t), H2(t) be pre-
dictable processes, then the predictable covariation process of the martingale integral
∫ t
0 H1(s)dM1(s)
and
∫ t
0 H2(s)dM2(s) is
〈
∫ t
0
H1(s)dM1(s),
∫ t
0
H2(s)dM2(s)〉 =
∫ t
0
H1(s)H2(s)d〈M1,M2〉(s). (44)
Lemma 4. For independent and identically distributed sequences of martingale {Mi} and predictable
process Hi(t), 1 ≤ i ≤ n, Var
( ∫ t
0 H1(u)dM1(u)
)
= E
( ∫ t
0 H1(u)dM1(u)
)2
= E
(
〈∫ t0 H1(u)dM1(u)〉) =
E
( ∫ t
0 H
2
1 (u)d〈M1〉(u)
)
can be estimated by
1
n
n∑
i=1
∫ t
0
H2i (u)d[Mi](u). (45)
Lemma 5 (Lenglart’s inequality). Let W be a local square integrable martingale. Then for all
δ, η > 0,
P( sup
t∈[0,1]
|W (t)| > η) ≤ δ
η2
+ P(〈W,W 〉(1) > δ). (46)
Basically the Lenglart’s inequality tells us that the convergence in probability of the supreme of
a martingale can be infered from its endpoint.
Lemma 6. Let Mi(t) be independent and identically distributed martingales with respect to the
filtration F(t), i = 1, ..., n, Hi(t) also be i.i.d. predictable processes, then
1√
n
n∑
i=1
∫ t
0
Hi(s)dMi(s)→p 0 uniformly in t ∈ [0, 1], (47)
if each sup0≤t≤1 |Hi(t)| = op(1).
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Proof. By Lemma 1 and 3,
〈 1√
n
n∑
i=1
∫ t
0
Hi(s)dMi(s)〉 = 1
n
n∑
i=1
n∑
j=1
∫ t
0
Hi(s)Hj(s)d〈Mi,Mj〉(s)
=
1
n
n∑
i=1
∫ t
0
H2i (s)d〈Mi〉(s).
Therefore,
P
(
sup
t∈[0,1]
∣∣ 1√
n
n∑
i=1
∫ t
0
Hi(s)dMi(s)
∣∣ > η) ≤ δ
η2
+ P
( 1
n
n∑
i=1
∫ 1
0
H2i (s)d〈Mi〉(s) > δ
)
.
Since 〈Mi〉 is increasing,
1
n
n∑
i=1
∫ 1
0
H2i (s)d〈Mi〉(s) ≤
1
n
n∑
i=1
[ sup
0≤s≤t
H2i (s)]〈Mi〉(t), (48)
if sup0≤t≤1 |Hi(t)| = op(1), so is
1
n
n∑
i=1
[ sup
0≤s≤t
H2i (s)]〈Mi〉(t) and
1√
n
n∑
i=1
∫ t
0
Hi(s)dMi(s), the latter
by Lemma 5.
The following proposition can be easily proved by mimicking the proof of Glivenko-Cantelli
theorem.
Proposition 1. Assume that (X1, Y1), . . . , (Xn, Yn) are independent and identically distributed pairs
of random variables with distribution function F (x, y). Also, X1 has finite first moment. Define
Gn(t) =
1
n
n∑
i=1
Xi1{[Yi,∞)}(t), (49)
and
G(t) = E[X11{[Y1,∞)}], (50)
then we have a similar result to Glivenko-Cantelli theorem, that is,
||Gn −G||∞ = sup
t∈R
|Gn(t)−G(t)| −→ 0. (51)
7.2 Additive hazards model for survival data
Proposition 2. Assuming (1) and (3), we have
λ¯(t|Xe, XI , Xo) = λ¯0(t) + βeXe + β¯o>Xo + ρ0∆, (52)
where λ¯0(t) = λ0(t)− ∂∂t log
[
E
{
exp(−t)}
]
.
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Proof. By the assumption (1), we have
S(t|Xe, XI , Xo, Xu) = exp
{
−
∫ t
0
[
λ0(s) + βeXe + β
>
o Xo +Xu
]
ds
}
.
Therefore, integrating out Xu we have,
S(t|Xe, XI , Xo)
= E[S(t|Xe, XI , Xo, Xu)|Xe, XI , Xo]
= E
[
exp
{− ∫ t
0
(λ0(s) + βeXe + β
>
o Xo + E(Xu|Xe, XI , Xo))
}
ds|Xe, XI , Xo
]
= E
[
exp
{− ∫ t
0
(λ0(s) + βeXe + β
>
o Xo + ρ0∆ + )ds
}|Xe, XI , Xo]
= exp
{− ∫ t
0
(λ0(s) + βeXe + β
>
o Xo + ρ0∆
}× E [ exp{−t}|Xe, XI , Xo]
= exp
{− ∫ t
0
(λ0(s) + βeXe + β
>
o Xo + ρ0∆)ds
}× E [ exp{−t}].
Now the hazard function becomes,
λ(t|Xe, XI , Xo) = − ∂
∂t
logS(t|Xe, XI , Xo)
= λ0(t)− ∂
∂t
log
[
E
{
exp(−t)}]+ βeXe + β>o Xo + ρ0∆,
where λ¯(t|Xe, XI , Xo) = λ¯0(t) + βeXe + β¯o>Xo + ρ0∆ is our new baseline hazard function.
In the following we give the regularity conditions and addition notation for the results of the
Theorems in section 2.
Condition 1. The covariates {Xei, XIi, Xoi} are bounded.
Note that
∆ˆ−∆ = −{Eˆ(Xe|XI , Xo)− E(Xe|XI , Xo)}
= −{g−1(X˜>αˆ)− g−1(X˜>αT )}
Condition 2. We assume that αˆ is consistent for αT , which implies that |∆ˆ − ∆| →p 0 with
Condition 1. We also assume that
√
n(αˆ− αT ) = I−1 · ( 1√
n
n∑
i=1
Ti) + op(1);
in other words,
√
n(αˆ− αT ) can be written into a sum of i.i.d. terms with finite variance plus one
op(1) term.
Remark 4. This Condition is usually fulfilled by the first step estimator, such as the maximum
likelihood estimator under the GLM.
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Condition 3. ∫ 1
0
λ¯0(t)dt <∞. (53)
Define S(j)(t) =
∑n
i=1 Yi(t)Z
⊗j
i /n for j = 0 and 1. Then by Gilvenko-Cantelli theorem there
exists a scalar and vector function s(0)(t) and s(1)(t) defined on [0, 1] such that
sup
t∈[0,1]
||S(j)(t)− s(j)(t)|| P−→ 0. (54)
Condition 4 (Asymptotic regularity conditions). s(0)(t) is bounded away from zero.
Condition 5. There exists a positive definite matrix Ω such that
1
n
n∑
i=1
∫ 1
0
Yi(t)
(
Z0i − s
(1)(t)
s(0)(t)
)⊗2
dt
a.s.−−→ Ω. (55)
Let Z0i = [Xei, X
>
oi ,∆i], Z¯0(t) =
∑n
l=1 Z0lYl(t)/
∑n
l=1 Yl(t), define
A1 =
n∑
i=1
∫ 1
0
(Zi − Z0i)dMi(t), (56)
A2 =
n∑
i=1
∫ 1
0
(Z¯(t)− Z¯0(t))dMi(t), (57)
A3 = ρ0
n∑
i=1
{∫ 1
0
(Zi − Z0i)Yi(t)dt
}
(∆i − ∆ˆi), (58)
A4 = ρ0
n∑
i=1
{∫ 1
0
(Z¯(t)− Z¯0(t))Yi(t)dt
}
(∆i − ∆ˆi). (59)
Lemma 7. A1, A2, A3, A4 are bounded in probability.
Proof. Notice that
Zi − Z0i = [0, 0, ∆ˆi −∆i]>,
where ∆ˆi −∆i = g−1(X˜>i αT ) − g−1(X˜>i αˆ) = (g−1)′(X˜>i αT ) + op(1). Therefore it suffices to check
the ∆ˆi −∆i components. Then the only nonzero entry of A1 is
n∑
i=1
∫ 1
0
{∆ˆi −∆i}dMi(t) =
{
− 1√
n
n∑
i=1
∫ 1
0
X˜>i (g
−1)′(X˜>i αT )dMi(t)
}√
n(αˆ− αT ) + op(1),
which is bounded in probability by central limit theorem. Next, we check the nonzero entry of A2,
n∑
i=1
∫ 1
0
∑n
l=1(∆ˆl −∆l)Yl(t)∑n
l=1 Yl(t)
dMi(t)
=
{
− 1√
n
n∑
i=1
∫ 1
0
∑n
l=1 X˜
>
l (g
−1)′(X˜>l αT )Yl(t)∑n
l=1 Yl(t)
dMi(t)
}√
n(αˆ− αT ) + op(1),
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where
∑n
l=1 X˜
>
l (g
−1)′(X˜>l αT )Yl(t)∑n
l=1 Yl(t)
will have a sup norm limit by Proposition 1. Name that limit
K(t), we will get
1√
n
n∑
i=1
∫ 1
0
∑n
l=1 X˜
>
l (g
−1)′(X˜>l αT )Yl(t)∑n
l=1 Yl(t)
dMi(t)
=
1√
n
n∑
i=1
∫ 1
0
{∑n
l=1 X˜
>
l (g
−1)′(X˜>l αT )Yl(t)∑n
l=1 Yl(t)
−K(t)
}
dMi(t) +
1√
n
n∑
i=1
∫ 1
0
K(t)dMi(t).
From Lemma 6 and Proposition 1, the first term will be op(1) and second will converge weakly.
Finally, rearranging the nonzero term in A3 gives
ρ0
n∑
i=1
(∆ˆi −∆i)(
∫ 1
0
Yi(t)dt)(∆ˆi −∆i)
=
√
n(αˆ− αT )>
{ρ0
n
n∑
i=1
(
∫ 1
0
Yi(t)dt)X˜iX˜
>
i (g
−1)′2(X˜>i αT )
}√
n(αˆ− αT ) + op(1),
together with the nonzero entry in A4,
√
n(αˆ− αT )>
{ρ0
n
n∑
i=1
∫ 1
0
∑n
l=1 X˜lYl(t)∑n
l=1 Yl(t)
Yi(t)X˜
>
i (g
−1)′2(X˜>i αT )dt
}√
n(αˆ− αT ) + o(1).
The boundedness of these two terms in probability follows from similar statement.
Proof of Theorem 1. With simple algebra, we have
U(β) =
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))(dNi(t)− Yi(t)β>Zidt)
=
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))(dMi(t) + Yi(t)dΛ0(t) + Yi(t)β>T Z0idt− Yi(t)β>Zidt)
=
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))(dMi(t) + Yi(t)β>T Z0idt− Yi(t)β>Zidt).
Plugging in the true parameter βT , we can decompose it into
U(βT ) =
1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))dMi(t) + ρ0
n
n∑
i=1
{∫ 1
0
(Zi − Z¯(t))Yi(t)dt
}
(∆i − ∆ˆi)
=
1
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
dMi(t)
+
ρ0
n
[ n∑
i=1
{∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
Yi(t)dt
}
X˜>i (g
−1)′(X˜>i αT )
]
(αˆ− αT )
+
1
n
A1 +
1
n
A2 +
1
n
A3 +
1
n
A4 + op(1).
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The first term is a sample mean of n i.i.d. martingale integrals of predictable functions, thus by
Law of Large Numbers is op(1). Following from Condition 2 and Law of Large Numbers again, the
second term will tend to zero in probability. The remaining terms are all op(1) by Lemma 7. Hence
U(βT ) = op(1).
Meanwhile, we can also express
U(βT ) = U(βT )− U(βˆ) =
{ 1
n
n∑
i=1
∫ 1
0
(Zi − Z¯(t))Yi(t)Zidt
}
(βˆ − βT ).
Solving for βˆ − βT we get,
βˆ − βT =
{ 1
n
n∑
i=1
∫ 1
0
Yi(t)(Zi − Z¯(t))⊗2dt
}−1
U(βT )
=
{ 1
n
n∑
i=1
∫ 1
0
Yi(t)
(
Z0i − s
(1)(t)
s(0)(t)
)⊗2
dt+ op(1)
}−1
U(βT ).
Condition 5 and U(βT ) = op(1) imply the consistency of βˆ from Slutsky’s theorem.
Proof of Theorem 2. Observe that
√
nU(βT )
=
1√
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
dMi(t)
+
ρ0
n
[ n∑
i=1
{∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
Yi(t)dt
}
X˜>i (g
−1)′(X˜>i αT )
]√
n(αˆ− αT )
+
1√
n
A1 +
1√
n
A2 +
1√
n
A3 +
1√
n
A4 + op(1)
=
1√
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
dMi(t) + Ψ
√
n(αˆ− αT ) + op(1),
where
Ψ = ρ0 E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
Y1(t)X˜
>
1 (g
−1)′(X˜>1 αT )dt
}
. (60)
With Condition 1, 2 and 3,
√
nU(βT ) can be written into a sum of i.i.d. random variables with
mean zero and finite second moments. Thus the Multivariate Central Limit Theorem together with
the Slutsky’s Theorem proves that our estimator is asymptotically normally distributed with mean
zero.
Lastly, we can compute the covariance matrix of this asymptotic normal distribution. Notice
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that the asymptotic covariance matrix of
√
nU(βT ) is by Condtion 2,
E
{(∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
dM1(t) + ΨI−1T1
)⊗2}
= E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
dM1(t)
}⊗2
+ΨI−1 E{T⊗21 }(I−1)>Ψ>
+2E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
dM1(t)T
>
1
}]
(I−1)>Ψ>
= Σ1 + Σ2 + 2 lim
n→∞E
{ n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
dMi(t)(αˆ− αT )>
}
Ψ>
= E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)⊗2
d[M1(t),M1(t)]
}
+ΨI−1 E(T⊗21 )(I−1)>Ψ>
+2E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
dM1(t)T
>
1
}]
(I−1)>Ψ>
= Σ1 + Σ2 + 2E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
dM1(t)T
>
1
}]
(I−1)>Ψ>, (61)
where
Σ1 = E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)2
d〈M1,M1〉(t)
}
, (62)
Σ2 = ΨΘΨ
>, (63)
and Θ is the variance-covariance matrix of the first step estimator. Note that the last term in
(61) is zero since it is still a martingale integral. Thus the asymptotic variance of our estimator√
n(βˆ − β) = Ω−1(√nU(βT ) + op(1)), where Ω is given in Condtion 5, is clearly Ω−1(Σ1 + Σ2)Ω−1.
To consistently estimate the variance, we just use their corresponding empirical parts. Specifically,
Σ1 can be instead estimated in the form of (13) by Lemma 4.
Proposition 3. Under (1), (3), (5) and Conditions 1,4,5, the cumulative baseline hazard function
estimator defined in (9) converges in probability to the true value Λ0T of Λ0(·) =
∫ ·
0 λ¯0(t)dt uniformly
in t ∈ [0, 1], where λ¯0(t) is the baseline hazard in equation (4), and the process
√
n{Λˆ0(·)−Λ0T (·)}
converges weakly to a zero-mean Gaussian process whose covariance function at (t, s), where 0 ≤
s ≤ t, can be consistently estimated by
n
n∑
i=1
∫ s
0
1
(
∑n
j=1 Yj(u))
2
dNi(u) + Cˆ
>(t)Ωˆ−1(Σˆ1 + Σˆ2)Ωˆ−1Cˆ(s) + Eˆ>(t)ΘˆEˆ(s)
−Cˆ>(t)Ωˆ−1Dˆ(s)− Cˆ>(s)Ωˆ−1Dˆ(t), (64)
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where
Cˆ(t) =
∫ t
0
Z¯(u)du, (65)
Dˆ(t) =
n∑
i=1
∫ t
0
Zi − Z¯(u)∑n
j=1 Yj(u)
dNi(u), (66)
Eˆ(t) = ρˆ0
n∑
i=1
X˜i(g
−1)′(X˜>i αˆ)
∫ t
0
Yi(u)∑n
j=1 Yj(u)
du. (67)
Proof of Proposition 3.
U1(Λ0(t), β, t) =
1
n
n∑
i=1
Mi(Λ0(t), β, t) =
1
n
n∑
i=1
∫ t
0
(dNi(u)− Yi(u)dΛ0(u)− Yi(t)β>Zidu),
note that U1(Λˆ0(t), βˆ, t) ≡ 0. Thus we have
U1(Λ0T (t), βˆ, t) = U1(Λ0T (t), βˆ, t)− U1(Λˆ0(t), βˆ, t) = 1
n
∫ t
0
n∑
i=1
Yi(u)d(Λˆ0(u)− Λ0T (u)).
Meanwhile, observe that
U1(Λ0T (t), βˆ, t)
=
1
n
n∑
i=1
∫ t
0
(dNi(u)− Yi(u)dΛ0T (u)− Yi(t)βˆ>Zidu)
=
1
n
n∑
i=1
∫ t
0
{dMi(u)− Yi(u)(βˆ>Zi − β>T Z0i)du}
=
1
n
n∑
i=1
∫ t
0
{
dMi(u)− Yi(u)(βˆ − βT )>Z0idu− Yi(u)ρˆ0(∆ˆi −∆i)du
}
=
1
n
n∑
i=1
∫ t
0
{
dMi(u)− Yi(u)(βˆ − βT )>Z0idu
+Yi(u)ρˆ0X˜
>
i (g
−1)′(X˜>i αT )(αˆ− αT )du
}
+ op(1).
where we shall emphasize that the op(1) here is uniformly over t ∈ [0, 1], which can be easily proved
with the help of Lemma 6. These together gives us that
Λˆ0(t)− Λ0T (t)
=
n∑
i=1
∫ t
0
1∑n
j=1 Yj(u)
dMi(u)−
{ n∑
i=1
∫ t
0
Yi(u)Z
>
i∑n
j=1 Yj(u)
du
}
(βˆ − βT )
−
{
ρˆ0
n∑
i=1
∫ t
0
Yi(u)X˜
>
i (g
−1)′(X˜>i αT )∑n
j=1 Yj(u)
du
}
(αˆ− αT ).
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It is easy to establish the uniform convergence in time t by checking for each term. For the weak
convergence, observe that
√
n(Λˆ0(t)− Λ0T (t))
=
√
n
n∑
i=1
∫ t
0
dMi(u)− Yi(u)(βˆ − βT )>Zidu− Yi(u)ρˆ0X˜>i (g−1)′(X˜>i αT )(αˆ− αT )du∑n
j=1 Yj(u)
=
1√
n
n∑
i=1
∫ t
0
1
s(0)(u)
dMi(u)−
(∫ t
0
s(1)(u)
s(0)(u)
du
)>√
n(βˆ − βT )
−
(∫ t
0
γ(u)
s(0)(u)
du
)>√
n(αˆ− αT ) + op(1),
where γ(u) = limn→∞ ρˆ0n
∑n
i=1 Yi(u)X˜
>
i (g
−1)′(X˜>i αT ). With Condition 4, Martingale Central Limit
Theorem 5.1.1 in Fleming and Harrington 31 can be employed to show that
√
n(Λˆ0(t) − Λ0T (t))
converges a mean zero Gaussian process with respect to the Skorohod topology with covariance
function at 0 ≤ s ≤ t obtained with the help of pointwise Multivariate Central Limit Theorem,
E
[{∫ t
0
1
s(0)(u)
dM1(u)−
(∫ t
0
s(1)(u)
s(0)(u)
du
)>
Ω−1
∫ 1
0
(
Z01 − s
(1)(u)
s(0)(u)
)
dM1(u)
−
(∫ t
0
γ(u)
s(0)(u)
du
)>
ΨI−1T1
}{∫ s
0
1
s(0)(u)
dM1(u)
−
(∫ s
0
s(1)(u)
s(0)(u)
du
)>
Ω−1
∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
dM1(t)−
(∫ s
0
γ(u)
s(0)(u)
du
)>
ΨI−1T1
}]
= E
{∫ s
0
1
(s(0)(u))2
d〈M1,M1〉(u)
}
+
(∫ t
0
s(1)(u)
s(0)(u)
du
)>
Ω−1 E
{∫ 1
0
(
Z01 − s
(1)(u)
s(0)(u)
)⊗2
d〈M1,M1〉(u)
}
Ω−1
(∫ s
0
s(1)(u)
s(0)(u)
du
)
+
(∫ t
0
γ(u)
s(0)(u)
du
)>
ΨE(T⊗21 )Ψ
>
(∫ s
0
γ(u)
s(0)(u)
du
)
−E
{(∫ t
0
s(1)(u)
s(0)(u)
du
)>
Ω−1
∫ t
0
Z01 − s
(1)(u)
s(0)(u)
s(0)(u)
d〈M1,M1〉(u)
}
−E
{(∫ s
0
s(1)(u)
s(0)(u)
du
)>
Ω−1
∫ t
0
Z01 − s
(1)(u)
s(0)(u)
s(0)(u)
d〈M1,M1〉(u)
}
−2E
{∫ t
0
1
s(0)(u)
dM1(u)T
>
1
}
(I−1)>Ψ>
(∫ s
0
γ(u)
s(0)(u)
du
)
+2E
{(∫ t
0
s(1)(u)
s(0)(u)
du
)>
Ω−1
∫ 1
0
(
Z01 − s
(1)(u)
s(0)(u)
)
dM1(u)T
>
1
}
(I−1)>Ψ>
(∫ s
0
γ(u)
s(0)(u)
du
)
where the last two terms can be proved to be zero by the similar approach as in the proof of Theorem
2. The remaining terms can be estimated by their empirical parts with the help of Lemma 4.
Proof of Theorem 3. The proof is similarly to the proof of Theorem 6, so omitted.
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7.3 Competing risks
Proposition 4. Assuming (19) and (3), we have
λ¯10(t|Xe, XI , Xo) = λ¯10(t) + βeXe + β¯o>Xo + ρ0∆. (68)
where λ¯10(t) = λ10(t)− ∂∂t log
[
E
{
exp
(− t)}].
Proof. The proof is completely parallel to that of Proposition 2 with 1− F1 in place of S.
In the following we give the regularity conditions and additional notation for the Theorems in
Section 3.
Define S(j)(t) =
∑n
i=1 Yi(t)wˆi(t)Z
⊗j
i /n for j = 0 and 1. Then there exists a scalar and vector
function s(0)(t) and s(1)(t), respectively, defined on [0, 1] such that for j = 0, 1,
sup
t∈[0,1]
||S(j)(t)− s(j)(t)|| P−→ 0. (69)
The above is guaranteed by Gilvenko-Cantelli theorem, Condition 2 and consistency of the Kaplan-
Meier estimator.
Condition 6 (Asymptotic regularity conditions). s(0)(t) is bounded away from zero.
Condition 7. There exists a positive definite matrix Ω such that
1
n
n∑
i=1
∫ 1
0
w˜i(t)Yi(t)
(
Z0i − s
(1)(t)
s(0)(t)
)⊗2
dt
a.s.−−→ Ω. (70)
Although w(t) is not adaptable to F1t−, we still have the following result:
Lemma 8. For any H(T, t) adaptable to Ft−, we have
E
{∫ 1
0
H(T, t)w(t)dM1(t)
}
= 0. (71)
Proof. The martingale M1(t) associated with the counting process N(t) has bounded variation. So
we can define the integral pathwisely, i.e.,∫ 1
0
H(T, t)w(t)dM1(t) = lim
max{ti−ti−1}→0
n∑
i=1
H(T, ti)w(ti)(M
1(ti)−M1(ti−1)) (72)
where {0 = t0 < t1 < ... < tn−1 < tn = 1} is a partition on [0, 1]. Notice that
E
{
H(T, ti)w(ti)(M
1(ti)−M1(ti−1))
}
= E
{
H(T, ti)E
(
w(ti)(M
1(ti)−M1(ti−1))
∣∣F1ti−1)},
where
E
{
w(ti)(M
1(ti)−M1(ti−1))
∣∣F1ti−1}
= E
{
(M1(ti)−M1(ti−1))E
(
w(ti)
∣∣F1ti)∣∣F1ti−1}
= E
{
(M1(ti)−M1(ti−1))E
(
1{C≥T∧ti}
G(ti)
G(X ∧ ti)
∣∣Fti)∣∣F1ti−1}
= E
{
(M1(ti)−M1(ti−1))G(ti)
∣∣F1ti−1} = 0.
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Thus it suffices to prove the result by dominated convergence theorem,
E
{∫ 1
0
H(T, t)w(t)dM1(t)
}
= E
{
lim
max{ti−ti−1}→0
n∑
i=1
H(T, ti)w(ti)(M
1(ti)−M1(ti−1))
}
= lim
max{ti−ti−1}→0
E
{ n∑
i=1
H(T, ti)w(ti)(M
1(ti)−M1(ti−1))
}
= 0.
Define
A1 =
1√
n
n∑
i=1
∫ 1
0
(Zi − Z0i)(wˆi(t)− wi(t))dM1i (t)), (73)
A2 =
1√
n
n∑
i=1
∫ 1
0
(Zi − Z0i)wi(t)dM1i (t), (74)
A3 =
1√
n
n∑
i=1
∫ 1
0
(Z¯(t)− Z¯0(t))(wˆi(t)− wi(t))dM1i (t), (75)
A4 =
1√
n
n∑
i=1
∫ 1
0
(Z¯(t)− Z¯0(t))wi(t)dM1i (t), (76)
A5 =
ρ0√
n
n∑
i=1
∫ 1
0
{(
Zi − Z¯(t)
)
−
(
Z0i − s
(1)(t)
s(0)(t)
)}
wˆi(t)Yi(t)(∆i − ∆ˆi)dt, (77)
Lemma 9. A1, A2, A3, A4, A5 all converge to 0 in probability as n→∞.
Proof. For the first term A1, by the same trick as in Fine and Gray 39 on the martingale expression
of Kaplan-Meier estimator we have,
1√
n
n∑
i=1
∫ 1
0
(Zi − Z0i)(wˆi(t)− wi(t))dM1i (t)
=
1√
n
n∑
i=1
∫ 1
0
(Zi − Z0i)ri(t)
G(t)1{T ∗i <t}
G(Xi ∧ t)
( n∑
j=1
∫ t
T ∗i
1∑n
k=1 1{T ∗k>u}
dM cj (u)
)
dM1i (t) + op(1)
=
1√
n
n∑
j=1
∫ 1
0
∑n
i=1(Zi − Z0i)wi(t)dM1i (t)1{T ∗i ≤u≤t}∑n
k=1 1{T ∗k>u}
dM cj (u) + op(1),
where M cj (u) is a martingale with respect to the censoring filtration
Fc(u) = {1{Xi≥t},1{Xi≤t,δi=0}, XIi, Xoi, Ji, Xei, t ≤ u, i = 1, ..., n}. (78)
Because the integrands are adaptable to this filtration after a careful analysis, the first term now
becomes a sum of martingale integrals, which by Lemma 6 is op(1).
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Next, the second term A2 becomes,
1√
n
n∑
i=1
∫ 1
0
{∆ˆi −∆i}wˆi(t)dM1i (t)
=
{ 1
n
n∑
i=1
∫ 1
0
X˜>i (g
−1)′(X˜>i αT )wi(t)dM
1
i (t)
}√
n(αˆ− αT ) + op(1),
by Lemma 8 and law of large numbers, it is op(1).
Proofs for A3 and A4 are exactly parallel to the first two but more laborious, which we omit
here.
For A5, we have
ρ0√
n
n∑
i=1
∫ 1
0
{(
Zi − Z¯(t)
)
wˆi(t)−
(
Z0i − s
(1)(t)
s(0)(t)
)
wˆi(t)
}
Yi(t)(∆i − ∆ˆi)dt
=
[ρ0
n
n∑
i=1
∫ 1
0
{(
Zi − Z¯(t)
)
wˆi(t)−
(
Z0i − s
(1)(t)
s(0)(t)
)
wˆi(t)
}
Yi(t)X˜
>
i (g
−1)′(X˜>i αT )dt
]√
n(αˆ− αT ),
which will tend to zero in probability by law of large numbers and Gilvenko-Cantelli theorem.
Proof of Theorem 4. By lemma 9, we can rewrite U(βT ) as
1
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
wi(t)dM
1
i (t) +
1
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
(wˆi(t)− wi(t))dM1i (t)
+
ρ0
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
wi(t)Yi(t)(∆i − ∆ˆi)dt+ op(1).
Notice that the first term is not a martingale integral since wi(t) is not adapted to the complete
data filtration F1(t). So partition it into
1
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
wi(t)dM
1
i (t)
=
1
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
1{Ci≥t}dM
1
i (t)
+
1
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)(
wi(t)− 1{Ci≥u}
)
dM1i (t).
The first term tends to zero from the conclusion in censoring complete situation. For the second
term, by Fubini-Toneli Theorem and the property of conditional expectation, we have
E
{∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)(
wi(t)− 1{Ci≥t}
)
dM1i (t)
}
= E
[
E
{∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)(
wi(t)− 1{Ci≥t}
)
dM1i (t)|Zi
}]
= E
[ ∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
E
{(
wi(t)− 1{Ci≥t}
)
dM1i (t)|Zi
}]
,
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where
E
{
w1(t)dM
1
1 (t)|Z1
}
= E
{
1{C1≥T1∧t}G(t)/G(T
∗
1 ∧ t)dM11 (t)|Z1
}
= E
{
G(t)dM11 (t)E
[
1{C1≥T1∧t}/G(T
∗
1 ∧ t)|Z0‘, T‘, Ji
]
|Z1
}
= E
{
G(t)dM11 (t)|Z1
}
= E
{
E
[
1{C1≥t}|Z01, T1, J1
]
dM11 (t)|Z1
}
= E
{
1{C1≥t}dM
1
1 (t)|Z01
}
.
Hence the second term also has zero expectation. This established the consistency of the first term
by Strong Law of Large Numbers. The remaining two terms can be handled by a similar way as we
do in the Lemma 9.
Proof of Theorem 5. Observe that
√
nU(βT ) =
1√
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
wi(t)dM
1
i (t)
+
{ρ0
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
wi(t)Yi(t)X˜
>
i (g
−1)′(X˜>i αT )dt
}√
n(αˆ− αT )
+
1√
n
n∑
i=1
∫ 1
0
(
Z0i − s
(1)(t)
s(0)(t)
)
(wˆi(t)− wi(t))dM1i (t) + op(1)
=
1√
n
n∑
i=1
∫ 1
0
(
Z0i +
s(1)(t)
s(0)(t)
)
wi(t)dM
1
i (t)−Ψ
√
n(αˆ− αT )
+
1√
n
n∑
i=1
∫ 1
0
q(t)
pi(t)
dM ci (t) + op(1),
where
Ψ = ρ0 E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
w1(t)Y1(t)X˜
>
1 (g
−1)′(X˜>1 αT )dt
}
,
q(t) = −E
{∫ 1
0
1{T ∗1<t≤u}w1(u)
(
Z01 − s
(1)(u)
s(0)(u)
)
dM11 (u)
}
,
pi(t) = P(T ∗1 ≥ t).
Therefore now
√
nU(βT ) has been written into a sum of i.i.d. random variables with mean zero
and finite second moments. By the Multivariate Central Limit Theorem and Slutsky’s theorem, our
estimator is asymptotically normal with mean zero and covariance matrix Ω−1(Σ1 + Σ2 + Σ3)Ω−1,
where the cross terms are zero by similar arguments as in the proof of Theorem 2; here the cross
terms are between the event martingale and the censoring martingale. Note that since we assume
that the event distribution and the censoring distribution are marginally independent, then
E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
w1(t)dM
1
1 (t)
∫ 1
0
q(t)
pi(t)
dM c1(t)
}
= E
{∫ 1
0
(
Z01 − s
(1)(t)
s(0)(t)
)
w1(t)dM
1
1 (t)
}
E
{∫ 1
0
q(t)
pi(t)
dM c1(t)
}
= 0.
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Proposition 5. Under (19), (3), (5) on the subdistribution hazard function and assumptions 1,6,7,
the baseline hazard function estimator defined in (23) converges to the baseline hazard function
uniformly after introducing the residual term and the process
√
n{Λˆ10(·)−Λ10T (·)} converges weakly
to a zero-mean Gaussian process whose covariance function at (t, s), where 0 ≤ s ≤ t, can be
consistently estimated by∫ s
0
n
∑n
i=1 wˆi(u)dNi(u)
(
∑n
j=1 wˆj(u)Yj(u))
2
+ Cˆ>(t)Ωˆ−1(Σˆ1 + Σˆ2 + Σˆ3)Ωˆ−1Cˆ(s) + Eˆ>(t)ΘˆEˆ(s)
+n
n∑
i=1
∫ 1
0
qˆt(u)qˆs(u)
pˆi2(u)
dN ci (u)− Cˆ>(t)Ωˆ−1Dˆ(s)− Cˆ>(s)Ωˆ−1Dˆ(t), (79)
where
Cˆ(t) =
∫ t
0
Z¯(u)du. (80)
Proof of Proposition 5. Similarly in the proof of Proposition 3 in the appendix, we will turn to
another score function,
U1(Λ0(t), β, t) =
1
n
n∑
i=1
∫ t
0
wˆi(u){dNi(u)− Yi(u)dΛ0(u)− Yi(t)β>Zidu},
note that U1(Λˆ0(t), βˆ, t) ≡ 0. Thus we have
U1(Λ0T (t), βˆ, t) = U1(Λ0T (t), βˆ, t)− U1(Λˆ0(t), βˆ, t) = 1
n
∫ t
0
n∑
i=1
wˆi(u)Yi(u)d(Λˆ0(u)− Λ0T (u)). (81)
In the meantime, observe that
U1(Λ0T (t), βˆ, t)
=
1
n
n∑
i=1
∫ t
0
wˆi(u){dNi(u)− Yi(u)dΛ0T (u)− Yi(t)βˆ>Zidu}
=
1
n
n∑
i=1
∫ t
0
wˆi(u){dMi(u)− Yi(u)(βˆ>Zi − β>T Z0i)du}
=
1
n
n∑
i=1
∫ t
0
wˆi(u){dMi(u)− Yi(u)(βˆ − βT )>Zidu− Yi(u)ρˆ0(∆ˆi −∆i)du}
=
1
n
n∑
i=1
∫ t
0
wˆi(u){dMi(u)− Yi(u)(βˆ − βT )>Z0idu− Yi(u)ρˆ0X˜>i (g−1)′(X˜>i αT )(αˆ− αT )du}.
These together gives us that
Λˆ0(t)− Λ0T (t)
=
n∑
i=1
∫ t
0
wˆi(u)∑n
j=1 wˆj(u)Yj(u)
dM1i (u)−
{ n∑
i=1
∫ t
0
wˆi(u)Yi(u)Z
>
0i∑n
j=1 wˆj(u)Yj(u)
du
}
(βˆ − βT )
−
{
ρˆ0
n∑
i=1
∫ t
0
wˆi(u)Yi(u)X˜
>
i (g
−1)′(X˜>i αT )∑n
j=1 wˆj(u)Yj(u)
du
}
(αˆ− αT ).
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Hence the uniform convergence can be established by an application of Gilvenko-Cantelli theorem.
For the weak convergence, we just need to check the variance-covariance function of
√
n(Λˆ0(t) −
Λ0T (t)). First note that
√
n(Λˆ0(t)− Λ0T (t))
=
√
n
n∑
i=1
∫ t
0
wi(u)∑n
j=1 wˆj(u)Yj(u)
dM1i (u) +
√
n
n∑
i=1
∫ t
0
wˆi(u)− wi(u)∑n
j=1 wˆj(u)Yj(u)
dM1i (u)
−√n
n∑
i=1
∫ t
0
wˆi(u)Yi(u)(βˆ − βT )>Z0i∑n
j=1 wˆj(u)Yj(u)
du
−√n
n∑
i=1
∫ t
0
wˆi(u)Yi(u)ρˆ0X˜
>
i (g
−1)′(X˜>i αT )(αˆ− αT )∑n
j=1 wˆj(u)Yj(u)
du
=
1√
n
n∑
i=1
∫ t
0
wi(u)
s(0)(u)
dM1i (u)−
1√
n
n∑
i=1
∫ t
0
wi(u)
∑n
j=1
∫ u
T ∗i
1∑n
k=1 1{T∗k>v}
dM cj (v)
s(0)(u)
dM1i (u)
−√n
(∫ t
0
s(1)(u)
s(0)(u)
du
)>
(βˆ − βT )−
√
n
(∫ t
0
γ(u)
s(0)(u)
du
)>
(αˆ− αT ) + op(1)
=
1√
n
n∑
i=1
∫ t
0
wi(u)
s(0)(u)
dM1i (u)
+
1√
n
n∑
j=1
∫ 1
0
1∑n
k=1 1{T ∗k>v}
∫ t
0
∑n
i=1wi(u)dM
1
i (u)1{T ∗i <v≤u}
s(0)(u)
dM cj (v)
−
(∫ t
0
s(1)(u)
s(0)(u)
du
)>√
n(βˆ − βT )−
(∫ t
0
γ(u)
s(0)(u)
du
)>√
n(αˆ− αT ) + op(1),
where
γ(t) = ρ0 E
{
wˆ1(t)Yi(t)X˜1(g
−1)′(X˜>1 αT )
}
(82)
in the above. With Condition 6, Martingale Central Limit Theorem 5.1.1 in Fleming and Harring-
ton 31 can again be employed to show that
√
n(Λˆ0(t)− Λ0T (t)) converges in the sense of Skorohod
topology to a mean zero Gaussian process with covariance function to be computed by similar way
as used in Theorem 2 and Proposition 3.
Proof of Theorem 6. The consistency simply follows from the results of Theorem 4, Proposition 5
in the appendix and that exp(−x) is continuously differentiable. For the asymptotic process, we
just resort to delta method and Donsker theorem.
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Figure 1: A causal directed acyclic graph (DAG) describing the causal relation between variables
Table 1: Simulation results for general survival data without competing risks.
Scenario Sample size Bias Emp. Var Est. Var Coverage
I 100 -0.15 6.10 6.80 95.8%
I 200 0.03 2.70 2.80 94.9%
I 400 -0.04 0.95 0.92 96.1%
I 800 -0.01 0.43 0.43 94.7%
I 1200 0.00 0.28 0.28 95.3%
II 100 0.06 2.10 2.00 94.6%
II 200 -0.05 0.93 0.89 94.4%
II 400 -0.05 0.45 0.42 96.0%
II 800 0.01 0.21 0.20 95.2%
II 1200 0.00 0.14 0.13 94.4%
III 100 0.12 62.50 64.44 95.7%
III 200 0.07 27.50 26.85 96.0%
III 400 0.07 13.74 12.53 94.9%
III 800 0.08 6.04 6.02 95.5%
III 1200 -0.04 4.09 3.96 95.5%
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Table 2: Simulation results under the competing risks model.
Scenario Sample size Bias Emp. Var Est. Var Coverage
I 100 0.07 3.60 3.40 94.8%
I 200 0.04 1.60 1.50 94.5%
I 400 0.04 0.77 0.74 94.0%
I 800 0.02 0.36 0.36 95.0%
I 1200 0.01 0.24 0.24 94.5%
II 100 0.13 4.10 4.30 95.3%
II 200 0.04 2.00 2.00 94.6%
II 400 -0.04 0.85 0.95 95.7%
II 800 0.01 0.43 0.46 95.8%
II 1200 -0.01 0.31 0.31 95.2%
III 100 0.23 134.80 128.90 95.7%
III 200 -0.16 53.38 58.34 95.0%
III 400 -0.12 26.17 27.14 95.9%
III 800 0.10 13.56 13.87 94.5%
III 1200 0.05 8.85 8.12 95.5%
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Table 3: Patient characteristics of the SEER-Medicare data set.
Radical prostatectomy Conservative management
n = 10977 n = 18829
Age
66-69 4852 (45.3%) 6925 (37.2%)
70-74 5859 (54.7%) 11694 (62.8%)
Marital Status
Married 7815 (73.0%) 12889 (69.2%)
Divorced 536 (5.0%) 1068 (5.7%)
Single 786 (7.3%) 1450 (7.9%)
Other 1574 (14.7%) 3212 (17.3%)
Race or Ethnity
Asian 206 (1.9%) 302 (1.6%)
Black 1022 (9.5%) 2495 (13.4%)
Hispanic 184 (1.7%) 222 (1.2%)
White 8973 (83.8%) 15047 (80.8%)
Other 326 (3.0%) 553 (3.0%)
Tumor Stage
T1 4132 (38.6%) 12059 (64.8%)
T2 6579 (61.4%) 6560 (35.2%)
Tumor Grade
Well differentiated 168 (1.6%) 140 (0.8%)
Moderately differentiated 5537 (51.7%) 9070 (48.7%)
Poorly differentiated 4793 (44.7%) 9153 (49.2%)
Undifferentiated 17 (0.2%) 26 (0.1%)
Cell type not determined 196 (1.8%) 230 (1.2%)
Prior Charlson comorbidity score
0 7217 (67.4%) 11868 (63.7%)
1 2301 (21.5%) 4260 (22.9%)
≥ 2 1193 (11.1%) 2491 (13.4%)
Diagnosis year
2001 345 (3.2%) 241 (1.3%)
2002 311 (2.9%) 268 (1.4%)
2003 277 (2.6%) 207 (1.1%)
2004 1284 (12.0%) 1908 (10.2%)
2005 1217 (11.4%) 1838 (9.9%)
2006 1334 (12.5%) 2252 (12.1%)
2007 1351 (12.6%) 2486 (13.4%)
2008 1291 (12.1%) 2372 (12.7%)
2009 1215 (11.3%) 2381 (12.8%)
2010 1020 (9.5%) 2263 (12.2%)
2011 1066 (10.0%) 2403 (12.9%)
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Table 4: Results of two stage residual inclusion IV analysis on overall survival with all two-way
interactions.
Variable Label Hazard difference Standard Errors
Two sided
P-value
Radical prostatectomy vs
Conservative management
-0.0012 0.00057 0.042
Residual term 0.0010 0.0006 0.083
Age 70-74 vs 66-69 0.0006 0.0005 0.24
Stage T2 vs T1 0.0005 0.0005 0.31
Married vs Other -0.0008 0.0007 0.23
Divorced vs Other 0.0011 0.0016 0.51
Single vs Other -0.0006 0.001 0.53
Asian vs Other -0.0004 0.0019 0.85
Black vs Other -0.0004 0.0013 0.75
Hispanic vs Other 0.0026 0.0022 0.24
White vs Other -0.0004 0.0011 0.7
Grade moderately differentiated vs
Well differentiated
0.0007 0.0004 0.052
Grade poorly differentiated vs
Well differentiated
0.0019 0.0006 0.0009
Grade undifferentiated vs
Well differentiated
0.0023 0.001 0.021
Grade cell type not determined vs
Well differentiated
0.0035 0.0011 0.0014
Prior Charlson comorbidity score
0 vs ≥ 2 -0.004 0.0010 < 0.0001
Prior Charlson comorbidity score
1 vs ≥ 2 -0.0026 0.0005 < 0.0001
2002 vs 2001 -0.00058 0.0003 0.022
2003 vs 2001 -0.00033 0.0003 0.33
2004 vs 2001 -0.0008 0.0004 0.032
2005 vs 2001 -0.001 0.0005 0.022
2006 vs 2001 -0.0013 0.0005 0.016
2007 vs 2001 -0.0013 0.0006 0.043
2008 vs 2001 -0.0014 0.0007 0.041
2009 vs 2001 -0.0017 0.0008 0.036
2010 vs 2001 -0.0018 0.0009 0.039
2011 vs 2001 -0.0018 0.0010 0.061
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Table 5: Results of two stage residual inclusion IV analysis on cancer specific survival with all
two-way interactions.
Variable Label Hazard difference Standard Errors
Two sided
P-value
Radical prostatectomy vs
Conservative management
-0.0002 0.0002 0.4
Residual term 0.0002 0.0002 0.5
Age 70-74 vs 66-69 0.0004 0.0002 0.084
Stage T2 vs T1 0.0003 0.0002 0.23
Married vs Other -0.0011 0.0004 0.0054
Divorced vs Other 0.000002 0.0009 1
Single vs Other -0.0005 0.0006 0.41
Asian vs Other -0.0012 0.0011 0.28
Black vs Other 0.0001 0.0007 0.88
Hispanic vs Other -0.0004 0.0009 0.63
White vs Other -0.0002 0.0006 0.69
Grade moderately differentiated vs
Well differentiated
0.0002 0.0002 0.21
Grade poorly differentiated vs
Well differentiated
0.0008 0.0003 0.0023
Grade undifferentiated vs
Well differentiated
0.0016 0.0006 0.013
Grade cell type not determined vs
Well differentiated
0.0013 0.0005 0.0075
Prior Charlson comorbidity score
0 vs ≥ 2 -0.0005 0.0004 0.24
Prior Charlson comorbidity score
1 vs ≥ 2 -0.0003 0.0002 0.18
2002 vs 2001 -0.0001 0.0001 0.26
2003 vs 2001 -0.0003 0.0002 0.059
2004 vs 2001 -0.0006 0.0002 0.0013
2005 vs 2001 -0.0008 0.0002 0.0008
2006 vs 2001 -0.0009 0.0003 0.0016
2007 vs 2001 -0.0010 0.0003 0.002
2008 vs 2001 -0.0011 0.0004 0.0017
2009 vs 2001 -0.0012 0.0004 0.002
2010 vs 2001 -0.0014 0.0005 0.0015
2011 vs 2001 -0.0015 0.0005 0.002
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Figure 2: Predicted overall survival (left) and cancer specific cumulative incidence (right) function
for a patient with pointwise 95% confidence intervals.
0 20 40 60 80 100 120 140
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
time (month)
Su
rv
iva
l p
ro
ba
bi
lity
0 20 40 60 80 100 120 140
0.
00
0.
05
0.
10
0.
15
time (month)
Cu
m
u
la
tiv
e
 in
ci
de
nc
e 
fu
nc
tio
n
36
